Unique formulation
6x faster
than decongestant pills.* Recommend for blocked and runny nose from colds
Ipratropium Bromide 0.06% Xylometazoline Hydrochloride 0.05%
*class-specific comparison (topical vs systemic decongestant) Product Information. Otrivine Extra Dual Relief 0.5mg/ml + 0.6mg/ml nasal spray, solution (xylometazoline hydrochloride and ipratropium bromide). Indications: Symptomatic treatment of nasal congestion and rhinorrhea in connection with common colds. Dosage and method of administration: Adults: 1 puff in each nostril up to 3 times daily. 6 hours min. between 2 doses. Max. 3 puffs daily into each nostril. Max. 7 days use. Paediatric population: Not for use under 18 years of age. Geriatrics: Limited experience of use in patients above 70 years of age. Contraindications: Hypersensitivity to ingredients, atropine or similar substances. After surgical operations where dura mater may have been penetrated. Patients with glaucoma or rhinitis sicca. Precautions: Use with caution in patients with hypertension, cardiovascular diseases, long QT syndrome, hyperthyroidism, diabetes mellitus, hypertrophy of the prostate, stenosis of the bladder, pheochromocytoma and a sensitivity to adrenergic substances. Use with caution in patients predisposed to angle closure glaucoma, epistaxis, paralytic ileus and cystic fibrosis. Immediate hypersensitivity including urticaria, angioedema and rash may occur. Max. duration of use is 7 days to prevent rebound effect. Avoid spraying in or around the eye. Side effects: Epistaxis, nasal dryness, dysgeusia, headache, nasal discomfort, nasal congestion, dry throat, throat irritation, rhinalgia, dry mouth, parasomnia, dizziness, tremor, eye irritation, dry eye, palpitations, tachycardia, nasal ulcer, sneezing, dyspepsia, nausea, hypersensitivity. Overdose: May cause dry mouth, accommodation difficulties and tachycardia. Treatment is symptomatic. Legal category: Pharmacy Only. Product Licence Number: PA 0678/131/001. MAH: GlaxoSmithKline Consumer Healthcare (Ireland) Limited, 12 Riverwalk, Citywest Business Campus, Dublin 24, Ireland. Full product information is available in the SPC. Additional information is available upon request. Text prepared: May 2020. Trade marks are owned by or licensed to the GSK group of companies. PM-IE-OTRI-20-00011